title: [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To analyse our series patients' data to assess its efficacy and safety of donor lymphocyte infusion (DLI) for Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) after allogeneic hematopoietic stem cell transplantation (HSCT).
  
  
  METHODS
  Patients received HSCT from November 2006 to November 2009 and diagnosed as EBV associated PTLD by pathological or clinical methods were enrolled in this study. Lymphocyte was prepared by COBE collector. Related haplo-donors were the alternative if the original donors was unavailable. A range of mononuclear cell (MNC) dose of (0.5 - 1.0) × 10(8)/kg was designed and the expected number of T lymphocyte included was at level of 10(7)/kg. Cyclosporine (CsA) trough concentration was kept in a therapeutic level.
  
  
  RESULTS
  Nine patients with PTLD received DLI 13 times, the median number of PBMC infused was 0.8 (0.16 - 1.03) × 10(8)/kg, CD(3)(+)T cell number was 4.2 (1.6 - 5.7) × 10(7)/kg. Seven patients received peripheral blood mononuclear cells (PBMC) from original haplo-identical donors, with 7 response and 6 complete remission. Defervescence occurred after 2 (1 - 5) d, and adenopathy began to recover in 6 (1 - 14) d after the initial infusion of leukocytes. Graft versus host diseases (GVHD) occurred in 6 recipients out of 7 evaluable patients, and all were controlled successfully. Three patients survived for 38, 23 and 3 months after PTLD.
  
  
  CONCLUSIONS
  In this small series cases, infusion of controlled dose of lymphocyte from primary donor is an effective and safe therapy for EBV associated PTLD after mismatched/haploidentical HSCT while the optimal regimen needs to be further studied.
authors.affiliation: Institute of Hematology, People's Hospital, Beijing University, Beijing 100044, China.
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Dai-hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Kai-yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Shi
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000209:etiology / Q000628:therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D004854:Herpesvirus 4, Human; D006801:Humans; D017710:Lymphocyte Transfusion; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy* / Q000821:virology; D008297:Male; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult